Navigation Links
Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
Date:11/8/2010

SAN DIEGO, Nov. 8, 2010 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that Christopher J. Reinhard, Cardium's Chairman and Chief Executive Officer will present at the LifeTech Capital Miami Medical Investors Conference on November 12, 2010 at 2:00 p.m. Eastern.  The conference will take place at the JW Marriott Marquis in Miami.  Although this presentation will not be webcast, investors can access the Company's presentation slides now available at Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.  

(Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations.  Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.  News from Cardium is located at www.cardiumthx.com.

Copyright 2010 Cardium Therapeutics, Inc.  All rights reserved. For Terms of Use Privacy Policy, please visit www.cardiumthx.com. Cardium Therapeutics™ Generx® and MedPodium™ are trademarks of Cardium Therapeutics, Inc.Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, Appexium™ and Linee™ are trademarks of Tissue Repair Company. (Other trademarks belong to their respective owners)


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
2. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
3. Cardium Regains Listing Compliance With NYSE Amex
4. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
5. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
6. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
7. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
8. Cardium Completes $6.0 Million Registered Direct Offering
9. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
10. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
11. Cardium Regains Listing Compliance with NYSE Amex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, today provided an ... in the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings ... Office.  The IPR was initiated on only certain claims ...
(Date:2/3/2016)... SAN DIEGO , Feb. 3, 2016 /PRNewswire/ ... medicine company with the first pluripotent stem cell-derived ... 1 diabetes in clinical-stage development, today announced that ... Janssen Pharmaceutical Companies of Johnson & Johnson, have ... BetaLogics group into ViaCyte.  The agreement provides ViaCyte ...
(Date:2/3/2016)... NEW BRUNSWICK, N.J. , Feb. 3, 2016 ... 30 grants totaling more than $1 million for ... who are working on health-related research that demonstrates ... , this round of funding for the New ... available for faculty members at these educational institutions— ...
(Date:2/3/2016)... 2016  Silk Therapeutics, Inc., today announced the closing of ... now raised a total of $10.25 million in Series A ... Series A2 round was led by existing investor The Kraft ... from new investors Lear Corporation and Highland Consumer Partners, as ... ; Richard Sackler , MD, with Summer Road, LLC; ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
Breaking Biology News(10 mins):